Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH and LH bind to specific receptors on ovarian granulosa and theca cells. This binding activates signaling pathways that promote follicular growth, estrogen production, and the final maturation and release of the oocyte, thereby facilitating ovulation and improving the chances of successful assisted reproduction.

The dose of Meriofert Set is individualized and determined by the prescribing fertility specialist based on the patient’s ovarian reserve, treatment protocol, and response monitoring. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

Meriofert Set is intended for use before conception to induce ovulation. Its safety during pregnancy has not been established, and it is not recommended for use while pregnant. Limited data are available for breastfeeding; therefore, it should only be used under specialist supervision if at all.

To order Meriofert Set, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Meriofert Set combines both FSH and LH in a single injectable formulation, whereas some alternatives provide only recombinant FSH (e.g., Gonal‑F) or separate LH preparations (e.g., Luveris). The combined approach may simplify dosing for certain protocols, but clinical choice depends on individual patient response, physician preference, and cost considerations.

Meriofert Set must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to refrigeration promptly.

Meriofert Set is administered by a qualified healthcare professional via intramuscular or subcutaneous injection. The injection site is typically the abdomen or thigh, and the exact technique, volume, and timing are determined by the treating physician according to the individual stimulation protocol.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, and respiratory distress; allergic reactions ranging from rash to anaphylaxis; and thromboembolic events such as deep‑vein thrombosis. Patients should be monitored closely for these complications during treatment.

Meriofert Set should not be used in individuals with known hypersensitivity to FSH, LH, or any excipients in the formulation. It is also contraindicated in patients with active ovarian cysts, uncontrolled thyroid disease, certain hormone‑dependent cancers, or severe uncontrolled medical conditions that increase the risk of OHSS or thromboembolism.